English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1822]
News [2727]
Articles [201]
Editorials [1]
Conferences [136]
elearning [13]
Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
3 Jun 2024
Chemotherapy before and after surgery may be new standard treatment for some...
Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany
Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer ( Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany )
3 Jun 2024
Osimertinib success in locally advanced EGFR-mutated NSCLC
Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA
Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )
3 Jun 2024
Adjuvant avelumab versus control does not significantly improve DFS but does...
Prof Pier Conte - University of Padova, Padova, Italy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )
3 Jun 2024
Adagrasib improves on docetaxel in previously treated NSCLC
Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado
Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )
3 Jun 2024
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible...
Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis ( Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain )
2 Jun 2024
Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS...
Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center...
Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel ( Dr Christos Kyriakopoulos - University of Wisconsin Carbone Cancer Center, Madison, USA )
2 Jun 2024
Atezolizumab versus placebo in combination with bevacizumab and non-platinum...
Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer ( Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany )
2 Jun 2024
Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy
Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China
Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )
1 Jun 2024
HER2DX assay and survival outcomes: An individual-patient level meta-analysis...
Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO)...
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa  - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 May 2024
Blood test may identify patients with non-small cell lung cancer subtype who...
Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA
Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )
12 Apr 2024
Urinary markers in the surveillance setting of non-muscle invasive bladder...
Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark
Urinary markers in the surveillance setting of non-muscle invasive bladder cancer ( Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark )
10 Apr 2024
<1...7891011...152>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top